Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976130 | 0.85 | CTSK (0.37) | CHRM2CHRM1CTSKMAPT | |
| SCHEMBL741450 | 0.83 | KCNA5 (0.34) | MAPTKMT2A | |
| SCHEMBL2761682 | 0.77 | KMT2A (0.37) | CHRM2CHRM1CTSKMAPTKMT2A | |
| SCHEMBL3977729 | 0.75 | KMT2A (0.36) | MAPTKMT2A | |
| SCHEMBL3974990 | 0.75 | KMT2A (0.36) | MAPTKMT2A | |
| SCHEMBL2243926 | 0.74 | KMT2A (0.35) | CHRM2CHRM1ELANECTSKKMT2A | |
| SCHEMBL3976510 | 0.74 | KMT2A (0.35) | MAPTKMT2A | |
| SCHEMBL2242527 | 0.74 | KCNA5 (0.31) | — | |
| SCHEMBL10306152 | 0.69 | GAA (0.39) | KMT2A | |
| SCHEMBL740950 | 0.69 | KCNA5 (0.31) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138352-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8003666-B2 | Hydrate for medical purposes | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20110144339-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7928232-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144339-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | ACSL3, NQO2, COASY | CHRM2 3958/4885CHRM1 3973/4885ELANE 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.